Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription


6 Blood
3 Br J Haematol
1 Clin Med Insights Oncol
1 Eur J Haematol
1 Haematologica
1 Leukemia
1 Oncol Rep
2 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. FOX LC
    Unraveling family ties in Hodgkin lymphoma.
    Blood. 2023;141:1240-1241.

  2. BAYKARA Y, Kurt H
    Low-grade follicular lymphoma with extensive marginal zone differentiation and expression of MUM1 and CD30.
    Blood. 2023;141:1363.

  3. LYNCH RC, Ujjani CS, Poh C, Warren EH, et al
    Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma.
    Blood. 2023 Mar 13:blood.2022019254. doi: 10.1182/blood.2022019254.
    PubMed         Abstract available

  4. CARBONE A, Gloghini A, Carlo Stella C
    Tumor microenvironment contribution to checkpoint blockade therapy. Lessons learned from Hodgkin lymphoma.
    Blood. 2023 Mar 10:blood.2022016590. doi: 10.1182/blood.2022016590.
    PubMed         Abstract available

  5. SANTORO A, Moskowitz AJ, Ferrari S, Carlo-Stella C, et al
    Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
    Blood. 2023 Mar 10:blood.2022017951. doi: 10.1182/blood.2022017951.

    Synthetic lethality in ATL.
    Blood. 2023;141:1096-1098.

    Br J Haematol

  7. GRUND J, Iben K, Reinke S, Buhnen I, et al
    Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma.
    Br J Haematol. 2023 Mar 15. doi: 10.1111/bjh.18762.
    PubMed         Abstract available

  8. SHANKAR A, Bomanji J
    An illuminating piece in the jigsaw of Hodgkin lymphoma risk stratification.
    Br J Haematol. 2023 Mar 17. doi: 10.1111/bjh.18764.
    PubMed         Abstract available

  9. MILGROM SA, Kim J, Pei Q, Lee I, et al
    Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study.
    Br J Haematol. 2023 Mar 15. doi: 10.1111/bjh.18734.
    PubMed         Abstract available

    Clin Med Insights Oncol

  10. TANAKA H, Mori E, Akutsu T, Saito S, et al
    Characteristics of Extranodal NK/T-Cell Lymphoma, Nasal Type, Compared with Nasal Diffuse Large B-cell Lymphoma.
    Clin Med Insights Oncol. 2023;17:11795549231156692.
    PubMed         Abstract available

    Eur J Haematol

  11. SHENG Z, Wang L
    Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: a network meta-analysis.
    Eur J Haematol. 2023 Mar 14. doi: 10.1111/ejh.13953.
    PubMed         Abstract available


  12. COOPER A, Kline J
    The lymphoma microenvironment comes of age in the R-CHOP era?
    Haematologica. 2023 Mar 16. doi: 10.3324/haematol.2022.282656.
    PubMed         Abstract available


  13. MANOS K, Chong G, Keane C, Lee ST, et al
    Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
    Leukemia. 2023 Mar 11. doi: 10.1038/s41375-023-01863.
    PubMed         Abstract available

    Oncol Rep

  14. ZENG H, Wang J, Xu B, Deng H, et al
    Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma.
    Oncol Rep. 2023;49:88.
    PubMed         Abstract available

    PLoS One

  15. SARA M, Minelli C, Broccia G, Vineis P, et al
    COVID-19 and non-Hodgkin's lymphoma: A common susceptibility pattern?
    PLoS One. 2023;18:e0277588.
    PubMed         Abstract available

  16. KOZAKI R, Yasuhiro T, Kato H, Murai J, et al
    Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics.
    PLoS One. 2023;18:e0282166.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  17. VLASEVSKA S, Garcia-Ibanez L, Duval R, Holmes AB, et al
    KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
    Proc Natl Acad Sci U S A. 2023;120:e2218330120.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.